Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Extended IBTROZI follow up highlights durable clinical response Safety profile remains consistent across treated patient ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
LUND, SE / ACCESS Newswire / March 18, 2026 / Cantargia (STO:CANTA) today reported the presentation of new pre-clinical data ...
In this analysis from the phase 3 EMPOWER‐Lung 1 study, researchers reported on quality of life in patients with advanced non‐small cell lung cancer and PD-L1 expression of 50% or more.
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
When Dan Hannon, 72, received guidance to have part of a lung taken out whether nodules were cancerous or not, he wanted a ...
The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At ...
(NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results